Rabies Immune Plasma Booster Study
Public ClinicalTrials.gov record NCT01063140. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Rabies Immune Plasma Booster Program - A Clinical Study Conducted as an Investigational New Drug Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Rabies immune globulin is a product that is lifesaving to unvaccinated individuals exposed to the rabies virus. Rabies immune globulin is made from plasma from immune donors. Currently the only practical method to obtain this plasma is to immunize normal volunteer Source Plasma donors and collect their plasma while titers are adequate. The use of rabies vaccine for immunization of normal Source Plasma donors is currently limited to a level that, while protective for the individual, is unsuitable for production of rabies immune globulin. The objective of this study is to obtain efficacy and safety data regarding the rabies boostering program to demonstrate that: 1. Rabies immune plasma production can be substantially increased by giving booster doses to previously immunized donors whose titers are below 10.0 IU/mL. 2. It is safe for normal Source Plasma donors to receive booster doses of rabies vaccine on a regular basis. This study utilizes two rabies vaccines approved by the FDA, Imovax® (Sanofi-Pasteur) and RabAvert® (Novartis).
Study identification
- NCT ID
- NCT01063140
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 491 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2008
- Primary completion
- Apr 30, 2010
- Completion
- Apr 30, 2010
- Last update posted
- Sep 6, 2015
2009 – 2010
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| CSL Donor Plasma Center | Tempe | Arizona | 85282 | — |
| CSL Donor Plasma Center | Rock Island | Illinois | 61201 | — |
| CSL Donor Plasma Center | Oak Park | Michigan | 48237 | — |
| CSL Donor Plasma Center | Saint Paul | Minnesota | 55104 | — |
| CSL Donor Plasma Center | Cleveland | Ohio | 44109 | — |
| CSL Donor Plasma Center | Springfield | Ohio | 45503 | — |
| CSL Donor Plasma Center | Oklahoma City | Oklahoma | 73103 | — |
| CSL Donor Plasma Center | Medord | Oregon | 97501 | — |
| CSL Donor Plasma Center | Knoxville | Tennessee | 37916 | — |
| CSL Donor Plasma Center | Salt Lake City | Utah | 84115 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01063140, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 6, 2015 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01063140 live on ClinicalTrials.gov.